Iteos Therapeutics Inc
NASDAQ:ITOS

Watchlist Manager
Iteos Therapeutics Inc Logo
Iteos Therapeutics Inc
NASDAQ:ITOS
Watchlist
Price: 7.2822 USD -2.25%
Market Cap: 266m USD
Have any thoughts about
Iteos Therapeutics Inc?
Write Note

Net Margin
Iteos Therapeutics Inc

-346.4%
Current
-106%
Average
-7.6%
Industry

Net Margin measures how much net income is generated as a percentage of revenues received. It helps investors assess if a company's management is generating enough profit from its sales and whether operating costs and overhead costs are being contained.

Net Margin
-346.4%
=
Net Income
-121.3m
/
Revenue
35m

Net Margin Across Competitors

Country Company Market Cap Net
Margin
US
Iteos Therapeutics Inc
NASDAQ:ITOS
272.1m USD
-346%
FR
Pharnext SCA
OTC:PNEXF
6T USD
-21 040%
US
Abbvie Inc
NYSE:ABBV
310.2B USD
9%
US
Amgen Inc
NASDAQ:AMGN
142B USD
13%
US
Gilead Sciences Inc
NASDAQ:GILD
115B USD
0%
US
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
101.6B USD
-5%
US
Epizyme Inc
F:EPE
94.1B EUR
-392%
AU
CSL Ltd
ASX:CSL
134.4B AUD
18%
US
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
78.5B USD
34%
US
Seagen Inc
F:SGT
39.3B EUR
-33%
NL
argenx SE
XBRU:ARGX
36B EUR
-14%
Country US
Market Cap 272.1m USD
Net Margin
-346%
Country FR
Market Cap 6T USD
Net Margin
-21 040%
Country US
Market Cap 310.2B USD
Net Margin
9%
Country US
Market Cap 142B USD
Net Margin
13%
Country US
Market Cap 115B USD
Net Margin
0%
Country US
Market Cap 101.6B USD
Net Margin
-5%
Country US
Market Cap 94.1B EUR
Net Margin
-392%
Country AU
Market Cap 134.4B AUD
Net Margin
18%
Country US
Market Cap 78.5B USD
Net Margin
34%
Country US
Market Cap 39.3B EUR
Net Margin
-33%
Country NL
Market Cap 36B EUR
Net Margin
-14%
No Stocks Found

Iteos Therapeutics Inc
Glance View

Market Cap
266m USD
Industry
Biotechnology

iTeos Therapeutics, Inc. engages in the development of biopharmaceuticals therapeutic products and services. The company is headquartered in Watertown, Massachusetts and currently employs 94 full-time employees. The company went IPO on 2020-07-24. The firm is focused on the discovery and development of differentiated immuno-oncology therapeutics for patients. The firm's pipeline includes two clinical-stage programs: EOS-448 and Inupadenant (EOS-850). The Company’s lead antibody product candidate, EOS-448, is an antagonist of T-cell immunoreceptor with Ig and ITIM domains (TIGIT), an immune checkpoint with multiple mechanisms of action, which leads to immunosuppression. Its EOS-850, is designed as a selective small molecule antagonist of the adenosine A2a receptor (A2AR) in the adenosine triphosphate (ATP) adenosine pathway. The firm is conducting an open-label multi-arm Phase I/II clinical trial of inupadenant in adult cancer patients with advanced solid tumors.

ITOS Intrinsic Value
2.127 USD
Overvaluation 71%
Intrinsic Value
Price

See Also

Discover More
What is Net Margin?

Net Margin measures how much net income is generated as a percentage of revenues received. It helps investors assess if a company's management is generating enough profit from its sales and whether operating costs and overhead costs are being contained.

Net Margin
-346.4%
=
Net Income
-121.3m
/
Revenue
35m
What is the Net Margin of Iteos Therapeutics Inc?

Based on Iteos Therapeutics Inc's most recent financial statements, the company has Net Margin of -346.4%.